TABLE 1.
Tests relevant to infectious disease included in the first WHO Essential Diagnostics Lista
| Category | Tests used in: |
|
|---|---|---|
| Primary health care facilities | Health care facilities with clinical laboratories (additional tests) | |
| General | General microscopy | Culture/blood culture |
| Urine dipstick/microscopy | Drug susceptibility testing | |
| Complete blood count | Comprehensive metabolic panel | |
| Whole-blood lactate | Blood gas testing | |
| Glucose | C-reactive protein | |
| Urinalysis (automated analyzer) | ||
| Disease specific (for infectious diseases) | HBsAg, HBeAg | HBV DNA (quantitative) |
| Anti-HCV | IgM anti-HBc, anti-HBs | |
| Anti-HIV, anti-HIV/p24 antigen | HCV cAg | |
| Malaria Ag (HRP2, pLDH) | HCV RNA (qualitative/quantitative) | |
| Malaria light microscopy | HIV DNA/RNA (qualitative/quantitative) | |
| TB microscopy | T lymphocyte CD4 count | |
| TB-LAMP | Cryptococcal antigen | |
| Tuberculin skin test | G6PD activity | |
| Syphilis (antitreponemal) | HPV DNA | |
| Combined antitreponemal/anti-HIV | TB: culture, DNA (cartridge based), LPA, DST, LAM, IGRA | |
| Blood product testing (HBV, HCV, HIV, syphilis, Chagas disease, HTLV) | ||
Anti-HBc, hepatitis B core antibodies; anti-HBs, hepatitis B surface antibodies; CD4, cluster of differentiation 4; CMP, comprehensive metabolic panel; DST, drug susceptibility testing; G6PD, glucose-6-phosphate dehydrogenase; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HCV cAg, HCV core antigen; HIV, human immunodeficiency virus; HPV, human papillomavirus; HRP2, histidine-rich protein 2; HTLV, human T-cell lymphotropic virus; IGRA, interferon gamma release assays; LAM, urine lipoarabinomannan; LAMP, loop-mediated isothermal amplification; LPA, line probe assay; pLDH, Plasmodium lactate dehydrogenase; TB, tuberculosis.